The Two Health Care Cost Crises January 18, 2024 From Drew Altman In this column, KFF President and CEO Drew Altman explores the nation’s twin health cost crises of affordability, especially for people who are sick and need a lot of health care, and national health spending, and why the solutions often work at cross purposes.
It’s Not a Health Care Election, But Health Issues Might Still Add Up February 28, 2024 From Drew Altman In this column, KFF President and CEO Drew Altman explores the potential for some health care issues—including abortion, drug costs and other affordability challenges—to influence enough voters in swing states to make a difference in this year’s presidential election.
How Many People with Employer-Sponsored Insurance Use the Drugs Slated for Medicare Price Negotiations August 14, 2024 Issue Brief Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations, according to a new analysis. The most used drug for people with employer-sponsored health insurance was Jardiance, a drug used to treat diabetes and…
Why Affordability Is the Big Tent February 20, 2024 From Drew Altman In this column, KFF President and CEO Drew Altman explores why the public’s concerns about out-of-pocket health costs make health care affordability the health policy issue most likely to resonate with voters across the political spectrum.
Public Opinion on Prescription Drugs and Their Prices August 21, 2023 Poll Finding This chart collection draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.